Search 

Founded in 2017, it has been the mission of Nanjing IASO Biotherapeutics (IASO BIO) to become a leading biopharmaceutical company focused on the discovery, development and commercialization of cell therapies in the field of oncology.

IASO BIO stands out through innovation, a world class facility, and an internationally renowned clinical research team that has treated more than 400 patients. Curing many who continually failed through multiple-lines of therapy, by means of detailed and thorough pathological analysis and follow up.

IASO BIO is dedicated to curing cancer using engineered autologous/allogenic T cell therapies designed to enhance the immune system's ability to recognize and eradicate cancer cells. Safety is dramatically enhanced via a proprietary procedure, minimizing the severity of CRS. Currently, IASO BIO is developing over 10 high-potential pharmaceutical products, targeting hematological tumors, solid tumors and virus associated tumors at different clinic stages.

to promote the business cooperation between Israel and Southwest China

One Top Chinese Pharma

Focus on cancer,intestinal disease

Kitov Pharma (NASDAQ:KTOV) is a clinical stage biopharmaceutical
company advancing first in class oncology therapies. We currently have one FDA
approved drug, Consensi™, and two oncology therapeutic candidates, CM-24 and NT-219:

• CM-24 is a clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with high potential to treat multiple oncology indications. CEACAM1 is associated with angiogenesis, is an
inter-cellular adhesion regulator and acts as a TIM-3 activator. High CEACAM1 expression is known to be associated with poor disease prognosis in a number of tumor types. Thus, blocking CEACAM1 with CM24 is associated with anti-angiogenic, immune access, and checkpoint release mechanisms. In a phase I
clinical study, CM-24 demonstrated a good safety profile and promising efficacy signals. We are developing CM-24 in a clinical collaboration with Bristol
Myers-Squibb for Phase 1/2 trial combining CM-24 with nivolumab in NSCLC and pancreatic cancer patients expressing high CEACAM1 levels.

• NT-219 is a first-in-class, dual inhibitor small molecule targeting IRS 1/2 and STAT3, two key signal transducers that promote cancer drug resistance. In preclinical studies, NT-219 demonstrated outstanding
efficacy in preventing acquired resistance and reversing tumor resistance when administered as a monotherapy and in combination with various oncology therapies. We are initiating first-in-man clinical trials with NT219, both as monotherapy and in combination with cetuximab (Erbitux™), with plans to expand combination studies in patients with recurrent or metastatic SCCHN cancer during 2020.

As an investment and management platform established by UK-listed company Cathay International Holdings Limited, Lansen has built up pharmaceutical segment, health segemtn and cosmetic segment. Lansen has been listed in Stock Exchange of Hong Kong Limited (SEHK) on May 7, 2010. Lansen's top products are in rheumatology and dermatology area, and Lansen has established an extensive distribution network, with more than 300 frontline sales staff and more than 1500 distributors. By licensing in promising products at commercial stage and clinical stage, or other cooperation patterns, Lansen plans to expand to more diseases medication market, including rheumaotlogy, dermatology, orthopedics and nephrology.

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company, wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark. LEO Pharma is a leader in medical dermatology and developes, manufactures and markets pharmaceutical drugs for medical dermatology and thrombosis in more than 100 countries globally. We offer patients and physicians highly innovative and well-established products in Psoriasis, Atopic Dermatitis, Eczema, Acne, Rosacea.
LEO Pharma is continuously striving to advance innovation to bring best-in-class and first-in-class medicines in medical dermatology and rare dermatological diseases to create a solid pipeline of assets. LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.
To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.

We are keen for In-Licensing Assets for Global and Regional Rights for following: (1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases (2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities. (3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets (4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology
In addition we LEO Pharma has two early stage assets available for partnering.

LEO 142397 (LP0184) is an oral, super selective JAK 1 inhibitor for inflammatory diseases. Product is ready for phase 1 studies. Compound is available for global licensing or acquisition.

LEO 134310 (LP0155) is a SEGRA compound. It is topical, supersoft, non-steroidal Glucocorticoid Receptor (GR) agonist with improved systemic and local safety profile. LP0155 has demonstrated efficacy in clinical phase 1 studies. Compound is available for global licensing or acquisition.